iBio, Inc. Common Stock (IBIO) Stock Forecast & Price Target
iBio, Inc. Common Stock · NASDAQ
$1.41-0.04 (-2.76%)
15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 5 firms covering iBio, Inc. Common Stock, 5 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. The target range is very wide, $2.00 to $7.00 (about 3.5x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $4.80 sits 240% above the current $1.41. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 4 to 5 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.08 next quarter toward $-0.31 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 ratings
Moderate Buy
Strong Buy00%
Buy5100%
Hold00%
Sell00%
Strong Sell00%
Based on 5 analysts giving stock ratings to iBio, Inc. Common Stock.
As of Jul, 5 of 5 firms rate IBIO a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
IBIO EPS & revenue forecast
EPS · NEXT QUARTER
$-0.08
Range $-0.09 – $-0.07 · 4 analysts · -30% YoY
Next period, 4 analysts expect iBio, Inc. Common Stock to earn $-0.08 a share (range $-0.09 – $-0.07), versus $-0.11 a year earlier. , growing to $-0.31 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 4 analysts · -100% YoY
Revenue is expected to reach $0 (range $0 – $0), -100.0% year-over-year., rising to $85.7K next year.
Top analysts covering iBio, Inc. Common Stock
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on IBIO.
#1
Keay Nakae
Chardan Capital · Rank #130
Buy
$5.00+254.6% to target
Overall win rate
41%
+ Follow
#2
Jay Olson
Oppenheimer · Rank #302
Buy
$5.00+254.6% to target
Overall win rate
32%
+ Follow
#3
CN
Catherine Novack
JonesTrading
Buy
$7.00+396.5% to target
Coverage
—
+ Follow
#4
Martin Auster
Raymond James
Buy
$5.00+254.6% to target
Coverage
—
+ Follow
#5
Catherine Novack
Jones Trading
Buy
$7.00+396.5% to target
Coverage
—
+ Follow
IBIO stock forecast FAQ
What is IBIO's average 12-month price target?+
The 5 analysts with a live target average $4.80 for iBio, Inc. Common Stock over the next 12 months, ranging from a $7.00 high to a $2.00 low.
Is IBIO stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 5 analyst ratings, 5 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for IBIO?+
The Street-high target is $7.00 (Jones Trading), and the Street-low is $2.00 (Leerink Partners). The average of all 5 active targets is $4.80.
How many Wall Street analysts cover IBIO?+
5 analysts have an active rating on iBio, Inc. Common Stock, and 5 firms carry a live 12-month price target.
Who is the most accurate analyst covering IBIO?+
Among analysts who currently cover IBIO, Keay Nakae of Chardan Capital has the strongest overall Quantellect track record (Rank #130). Their current call is Buy with a $5.00 target.
What is iBio, Inc. Common Stock's projected EPS for next quarter?+
The consensus estimate is $-0.08 per share (range $-0.09 – $-0.07) across 4 analysts, rising to $-0.31 the following year.
How much revenue is iBio, Inc. Common Stock expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0), growing to $85.7K next year.
Have analysts been upgrading or downgrading IBIO lately?+
As of Jul, 5 of 5 firms rate IBIO a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their IBIO calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
